FDA stepping up actions against PGx testing, forcing some labs to stop reporting drug information

Genome Web |
August 2019
Press

Researchers led by Robert Green at Brigham and Women’s Hospital looked at whether consumers getting direct-to-consumer genetic testing were using PGx tests to change treatment decisions. Although this study relied on self-reported data from participants, it suggests that less than 1 percent could have made unsupervised medication changes based on their genetic test results.